LARIMAR THERAPEUTICS, INC. (LRMR) Cash and securities
- Total cash · latest quarter (USD): Value $156.27M; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $156.27M | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. $92.69M + $63.58M ≈ $156.27M |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 92.69M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 63.58M USD | Debt Securities, Available-for-sale, Current |
| Cash and current securities | 156.27M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | $156.27M | (m) | $92.69M | $63.58M | (m) |
| 2026-03-31 | $200.38M | (m) | $177.91M | $22.47M | (m) |
| 2025-12-31 | $136.85M | (m) | $85.41M | $51.44M | (m) |
| 2025-09-30 | $175.44M | (m) | $90.14M | $85.30M | (m) |
| 2025-06-30 | $138.52M | (m) | $20.59M | $117.94M | (m) |
| 2025-03-31 | $157.53M | (m) | $21.13M | $136.40M | (m) |
| 2024-12-31 | $183.45M | (m) | $33.22M | $150.24M | (m) |
| 2024-09-30 | $203.71M | (m) | $35.07M | $168.64M | (m) |
| 2024-06-30 | $226.06M | (m) | $32.31M | $193.75M | (m) |
| 2024-03-31 | $227.30M | (m) | $110.13M | $117.17M | (m) |
| 2023-12-31 | $86.79M | (m) | $26.75M | $60.04M | (m) |
| 2023-09-30 | $95.59M | (m) | $38.72M | $56.87M | (m) |
| 2023-06-30 | $104.20M | (m) | $94.32M | $9.88M | (m) |
| 2023-03-31 | (m) | (m) | $111.52M | (m) | (m) |
| 2022-12-31 | $118.43M | (m) | $26.82M | $91.60M | (m) |
| 2022-09-30 | $124.70M | (m) | $86.05M | $38.65M | (m) |
| 2022-06-30 | $54.92M | (m) | $19.74M | $35.19M | (m) |
| 2022-03-31 | (m) | (m) | $62.56M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $70.10M | (m) | (m) |
| 2021-09-30 | $78.02M | (m) | $71.53M | $6.50M | (m) |
| 2021-06-30 | $70.63M | (m) | $70.63M | $0.00 | (m) |
| 2021-03-31 | $81.44M | (m) | $62.19M | $19.25M | (m) |
| 2020-12-31 | $92.64M | (m) | $68.15M | $24.49M | (m) |
| 2020-09-30 | $102.31M | (m) | $101.31M | $1.00M | (m) |
| 2020-06-30 | $113.68M | (m) | $112.67M | $1.01M | (m) |
| 2020-03-31 | $63.88M | (m) | $38.98M | $24.91M | (m) |
| 2019-12-31 | $70.26M | (m) | $27.21M | $43.05M | (m) |
| 2019-09-30 | $82.01M | (m) | $43.34M | $38.67M | (m) |
| 2019-06-30 | $91.66M | (m) | $37.24M | $54.42M | (m) |
| 2019-03-31 | $104.67M | (m) | $36.42M | $68.24M | (m) |
| 2018-12-31 | $118.07M | (m) | $49.33M | $68.73M | (m) |
| 2018-09-30 | $127.83M | (m) | $45.14M | $82.69M | (m) |
| 2018-06-30 | $75.85M | (m) | $40.74M | $35.10M | (m) |
| 2018-03-31 | $89.07M | (m) | $45.73M | $43.34M | (m) |
| 2017-12-31 | $102.05M | (m) | $40.78M | $61.27M | (m) |
| 2017-09-30 | $93.18M | (m) | $19.19M | $73.99M | (m) |
| 2017-06-30 | $105.99M | (m) | $31.73M | $74.27M | (m) |
| 2017-03-31 | $116.94M | (m) | $28.63M | $88.30M | (m) |
| 2017-01-01 | (m) | (m) | $32.35M | (m) | (m) |
| 2016-12-31 | $129.19M | (m) | $32.35M | $96.84M | (m) |
| 2016-09-30 | $138.66M | (m) | $24.86M | $113.80M | (m) |
| 2016-06-30 | $150.47M | (m) | $20.03M | $130.44M | (m) |
| 2016-03-31 | $166.18M | (m) | $31.45M | $134.73M | (m) |
| 2015-12-31 | $185.08M | (m) | $35.59M | $149.48M | (m) |
| 2015-09-30 | $203.95M | (m) | $38.76M | $165.19M | (m) |
| 2015-06-30 | (m) | (m) | $83.57M | (m) | (m) |
| 2015-03-31 | (m) | (m) | $106.93M | (m) | (m) |
| 2014-12-31 | (m) | (m) | $58.10M | (m) | (m) |
| 2014-09-30 | (m) | (m) | $127.03M | (m) | (m) |
| 2014-06-30 | (m) | (m) | $134.23M | (m) | (m) |
| 2014-03-31 | (m) | (m) | $38.48M | (m) | (m) |
| 2013-12-31 | (m) | (m) | $35.52M | (m) | (m) |
| 2013-09-30 | (m) | (m) | $4.84M | (m) | (m) |
| 2013-06-30 | (m) | (m) | $8.45M | (m) | (m) |
| 2012-12-31 | (m) | (m) | $9.94M | (m) | (m) |
| 2011-12-31 | (m) | (m) | $1.47M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |